News
Roche nabs breakthrough tag for TIGIT cancer immunotherapy
Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough status from the FDA.
